ENLIVEN THERAPEUTICS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value
ENLIVEN THERAPEUTICS, INC. (ELVN) had Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value of $27.80 million as of 2025-12-31, per its 10-K filed 2026-03-03.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue · last filed 2026-03-03
- 2025-12-31: Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value $27.80M.
- 2024-12-31: Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value $69.19M.
- 2023-12-31: Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value $35.69M.
- 2022-12-31: Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value $1.19M; Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value as first filed $1.01M.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value | Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value as first filed |
|---|---|---|
| 2025-12-31 | $27.80M 10-K · filed 2026-03-03 | |
| 2024-12-31 | $69.19M 10-K · filed 2026-03-03 | |
| 2023-12-31 | $35.69M 10-K · filed 2025-03-13 | |
| 2022-12-31 | $1.19M 10-K · filed 2024-03-14 | $1.01M 10-K · filed 2023-02-10 |
| 2022-09-30 | $264.00K 10-Q · filed 2022-10-25 | |
| 2022-06-30 | $9.00K 10-Q · filed 2022-08-03 | |
| 2022-03-31 | $219.00K 10-Q · filed 2022-05-06 | |
| 2021-12-31 | $9.66M 10-K · filed 2024-03-14 | |
| 2021-09-30 | $254.00K 10-Q · filed 2021-11-09 | |
| 2021-06-30 | $3.83M 10-Q · filed 2021-08-06 | |
| 2021-03-31 | $4.65M 10-Q · filed 2021-05-11 | |
| 2020-12-31 | $3.51M 8-K · filed 2023-06-23 | $24.26M 10-K · filed 2021-03-05 |
| 2020-09-30 | $24.51M 10-Q · filed 2020-11-05 | |
| 2020-06-30 | $41.58M 10-Q · filed 2020-08-14 | |
| 2020-03-31 | $21.30M 10-Q · filed 2020-05-07 | |
| 2019-12-31 | $15.15M 10-K · filed 2021-03-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 |